P Vergara-Aragon, G Valverde-Aguilar, Ruth Bustamante-Garcia, Teresa Neri-Gomez and Marcela Palomero-Rivero
Universidad Nacional Autonoma de Mexico, Mexico
CICATA-LegarÃ?Â?Ã?Âa Instituto Politecnico Nacional, Mexico
Centro Medico Nacional Siglo XXI- IMSS, Mexico
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
The aim of this study was to evaluate the effect that applies an amorphous matrix with dopamine obtained by sol-gel method
produces in the caudate nucleus of induced hemiparkinsonian rats. The estimation of this matrix with dopamine effects was
evaluated by behavioral, histological and neurochemical tests. We used 64 male Wistar rats about 250-300 g aleatory divided in 4
groups of 8 each one with free access to water and food. The groups that conformed each experimental block were: Control (C),
Lesioned (Lx); Lesion + implant (Lx-IMP) and Implant (Imp). The behavioral evaluation was made on day 1, 21, 90, 180 and 360 of
the experimental phase. It was made an evaluation of the exploratory behavior and induced twist. We exanimated the fine motor in
the reach test, number of induced twist with APO and we determinate the DA levels by HPLC in the SN and NC. The results showed
differences (p<0.05) between Lx group compared with control in the test made. Also, we found statistically significant differences
between Lx and Lx+Imp groups with reports of improvement in the implant group. These results suggest that the dopamine was
released through the nanoporos that has the matrix with dopamine walls resulting in a frank rise in the number of squares walk in
the open field test for the Lx+Imp group, less number of induced rotations, better performance in the reaching task and superior
dopamine levels compare with Lx group. With these results we can conclude that a matrix with dopamine implanted in the NC of
hemiparkinsonian rats causes a beneficial effect that we attributed to the released dopamine in the rats with hemiparkinsonism +
implant caudate nucleus.
Acknowledgement: The authors acknowledge the financial supports of SIP 20170002, DGAPA-PAPIIT IT200813 and DGAPA
PAPIIT IT202417
P Vergara-Aragón has done her MD and PhD in Psychological Research and has worked in the Faculty of Medicine UNAM in Mexico for more than 30 years. She is collaborating with the Physics Institute of the National Polytechnique Institute. Her research is focused on the field of Parkinson Disease (PD): Study of the nigrostriatal pathway degeneration, and involved mechanism caused by rotenone and 6-OHDA; stabilization of dopamine and its use as treatment for PD; the study of the effects produced in vivo of a TiO2 amorphous matrix as a reservoir for dopamine in a PD model in rats; description of the cognitive implications of PD in patients; toxicity and biological implications of rotenone exposure in animal models.
Email: paty_ver@hotmail.com
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report